Favipiravir: positive effect for mild to moderate cases of COVID-19

[sammmy]

Glenmark’s phase III favipiravir study finds drug speeds clinical improvement for some patients

Favipiravir COVID-19 studies summary:

Chinese clinical trials showed favipiravir to be ‘clearly effective’ – patients tested negative for the virus in an average of just four days, compared to 11 days for controls. Symptoms improved alongside reduced viral load, with lung function improving in 91% of patients on the drug, vs 62% of those without. In a Russian trial, body temperature in 68% of patients on favipiravir returned to normal in half the time of those in the control group. A trial in Japan, however, showed limited effect in people with higher viral load, suggesting it’s most likely to be of use in mild to moderate cases. Trials are also underway worldwide exploring the efficacy of favipiravir alone and in tandem with other drugs.

 

[Nelson Vergel]

Relief Therapeutics Sees 60% to 70% Chance of COVID-19 Drug Approval

Relief Therapeutics' chairman said he was optimistic its RLF-100 (aviptadil) drug will win approval for treating COVID-19 patients in a matter of months.

www.medscape.com